<DOC>
	<DOC>NCT00127023</DOC>
	<brief_summary>This is a study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals combined measles-mumps-rubella varicella candidate vaccine given to healthy children in their second year of life.</brief_summary>
	<brief_title>Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases</brief_title>
	<detailed_description>Separate injections of the licensed Priorix (MMR vaccine) and Varilrix (chickenpox vaccine) serve as control.</detailed_description>
	<mesh_term>Measles</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Mumps</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male or female subject between 1113 months of age (i.e. from 11 month birthday until the day before the 14 month birthday) at the time of the first vaccination. History of previous measles, mumps, rubella and/or varicella vaccination or disease, or known exposure to any of these diseases within 30 days prior to the start of the trial Planned administration of a vaccine not foreseen by the study protocol from 30 days prior to each vaccination until 4256 days after each vaccination</criteria>
	<gender>All</gender>
	<minimum_age>11 Months</minimum_age>
	<maximum_age>21 Months</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Prophylaxis measles, mumps, rubella and chickenpox</keyword>
</DOC>